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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
beta-glucans from oats and barley and maintenance of normal blood 
LDL-cholesterol concentrations (ID 1236, 1299), increase in satiety leading 
to a reduction in energy intake (ID 851, 852), reduction of post-prandial 
glycaemic responses (ID 821, 824), and “digestive function” (ID 850) 
pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol 
concentrations, increase in satiety leading to a reduction in energy intake, reduction of post-prandial 
glycaemic responses, and “digestive function”. The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The foods/food constituents that are the subject of the health claims are “barley grain fibre”, “oat 
grain fibre”, “oats beta-glucan”, “barley beta-glucan”, “barre céréalière diététique contenant de 
l'avoine”, and “oatbran and oatbran products”. From the conditions of use and references provided, 
the Panel assumes that the food constituent responsible for the claimed effects is beta-glucans from 
oats and barley. The Panel considers that beta-glucans from oats and barley are sufficiently 
characterised. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1608, EFSA-Q-2008-1611, EFSA-Q-2008-1637, 
EFSA-Q-2008-1638, EFSA-Q-2008-1639, EFSA-Q-2008-1974, EFSA-Q-2008-2037, adopted on 25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Gut/Immune: Jean-Louis Bresson, Maria Carmen Collado, Miguel Gueimonde, Daisy Jonkers, Martinus Løvik, Bevan 
Moseley, Maria Saarela, Seppo Salminen, Yolanda Sanz, Stephan Strobel, Daniel Tomé and Hendrik van Loveren. The 
members of the Claims Sub-Working Group on Weight Management/Satiety/Glucose and Insulin Control/Physical 
Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
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Maintenance of normal blood LDL-cholesterol concentrations 
The claimed effects are “fibres solubles (beta-glucane) et cholestérol sanguin” and “blood cholesterol 
level”. The Panel assumes that the target population is the general population. In the context of the 
proposed wordings, the Panel assumes that the claimed effects refer to the maintenance of normal 
blood LDL-cholesterol concentrations. 
A claim on beta-glucans and maintenance of normal blood cholesterol concentrations has already 
been assessed with a favourable outcome. 
Increase in satiety leading to a reduction in energy intake 
The claimed effect is “increases satiety, prolongs satiety”. The Panel assumes that the target 
population is the general population. The Panel considers that an increase in satiety leading to a 
reduction in energy intake, if sustained, might be a beneficial physiological effect. 
None of the studies provided tested the sustainability of an effect of beta-glucans from oats or barley 
on appetite ratings and subsequent energy intake. Thus, no conclusions can be drawn from the studies 
provided for the scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of beta-glucans from oats and barley and a sustained 
increase in satiety leading to a reduction in energy intake. 
Reduction of post-prandial glycaemic responses 
The claimed effect is “carbohydrate metabolism and insulin sensitivity”. The Panel assumes that the 
target population is individuals who wish to reduce their post-prandial glycaemic responses. In the 
context of the proposed wordings, the Panel assumes that the claimed effect refers to the reduction of 
post-prandial glycaemic responses. The Panel considers that reduction of post-prandial glycaemic 
responses (as long as post-prandial insulinaemic responses are not disproportionally increased) may 
be a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that intervention studies in healthy subjects 
consistently show an effect of oat and barley beta-glucans in decreasing post-prandial glycaemic 
responses without disproportionally increasing post-prandial insulinaemic responses at doses of about 
4 g per 30 g of available carbohydrates in bread and pasta products when consumed alone or in the 
context of a meal, and that the mechanism by which beta-glucans could exert the claimed effect is 
well established. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has been 
established between the consumption of beta-glucans from oats and barley and a reduction of 
post-prandial glycaemic responses. 
The Panel considers that in order to obtain the claimed effect, 4 g of beta-glucans from oats or barley 
for each 30 g of available carbohydrate should be consumed per meal. The target population is 
individuals who wish to reduce their post-prandial glycaemic responses. 
“Digestive function” 
The claimed effect is “beta-glucan improves digestive function”. The Panel assumes that the target 
population is the general population. The Panel considers that “improving digestive function” without 
specification of the nutrients which are the target of the claim is not sufficiently defined. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The foods/food constituents that are the subject of the health claims are “barley grain fibre”, “oat 
grain fibre”, “oats beta-glucan”, “barley beta-glucan”, “barre céréalière diététique contenant de 
l'avoine”, and “oatbran and oatbran products”. 
From the conditions of use and references provided, the Panel assumes that the food constituent 
responsible for the claimed effects is beta-glucans from oats and barley. 
Beta-glucans are soluble cereal fibres. They are non-starch polysaccharides composed of glucose 
molecules in long linear glucose polymers with mixed β-(1→4) and β-(1→3) links with an 
approximate distribution of 30 % to 70 %. Their molecular weight varies from 50 to 2,000 kDa. 
Beta-glucans occur naturally in the bran of cereal grasses such as barley (~7 %), oats (~5 %), rye and 
wheat (1-2 %), and are measurable in foods by established methods. This opinion applies to beta-
glucans naturally present in foods, and added to foods. 
The mixed linkages are important for their physical properties, such as solubility and viscosity. Their 
viscosity is a function of the concentration of dissolved beta-glucans, and of their molecular weight 
(Wood et al., 2000), and further depends on differences in raw materials, processing and methods of 
determination. 
The Panel considers that the food constituent, beta-glucans from oats and barley, which is the subject 
of the health claims, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Maintenance of normal blood LDL-cholesterol concentrations (ID 1236, 1299) 
The claimed effects are “fibres solubles (beta-glucane) et cholestérol sanguin” and “blood cholesterol 
level”. The Panel assumes that the target population is the general population. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal blood LDL-cholesterol concentrations. 
A claim on beta-glucans and maintenance of normal blood cholesterol concentrations has already 
been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009). 
2.2. Increase in satiety leading to a reduction in energy intake (ID 851, 852) 
The claimed effect is “increases satiety, prolongs satiety”. The Panel assumes that the target 
population is the general population. 
Satiety is the decrease in motivation to eat after consumption of food. The effect may persist up to 
several hours, may reduce energy intake either at the next meal or across the day and, if sustained, 
may lead to a reduction in body weight. 
The Panel considers that an increase in satiety leading to a reduction in energy intake, if sustained, 
might be a beneficial physiological effect. 
2.3. Reduction of post-prandial glycaemic responses (ID 821, 824) 
The claimed effect is “carbohydrate metabolism and insulin sensitivity”. The Panel assumes that the 
target population is individuals who wish to reduce their post-prandial glycaemic responses. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
reduction of post-prandial glycaemic responses. 
Postprandial glycaemia is interpreted as the elevation of blood glucose concentrations after 
consumption of a food and/or meal. This function is a normal physiological response that varies in 
magnitude and duration, and which may be influenced by the chemical and physical nature of the food 
or meal consumed, as well as by individual factors (Venn and Green, 2007). Decreasing post-prandial 
glycaemic responses may be beneficial to subjects with, for example, impaired glucose tolerance, as 
long as post-prandial insulinaemic responses are not disproportionally increased. Impaired glucose 
tolerance is common in the general adult population. 
The Panel considers that the reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect. 
2.4. “Digestive function” (ID 850) 
The claimed effect is “beta-glucan improves digestive function”. The Panel assumes that the target 
population is the general population. 
Improved digestion or absorption of nutrients might be considered as beneficial physiological effects 
in a situation where digestion or absorption is a limiting factor for the maintenance of adequate status 
of the nutrient. The Panel considers that “improving digestive function” without identification of the 
nutrients which are the target of the claim is not sufficiently defined. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
Beta-glucans from oats and barley related health claims 
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3. Scientific substantiation of the claimed effect 
3.1. Increase in satiety leading to a reduction in energy intake (ID 851, 852) 
The two references provided for the scientific substantiation of the claim reported on human 
intervention studies which assessed the effects of oat or barley products on appetite ratings (including 
satiety) after eating the test food on a single occasion (Berti et al., 2005; Granfeldt et al., 1994). One 
of the studies also reported on the effects of barley and oat product consumption (on a single 
occasion) on subsequent energy intake (Berti et al., 2005). The Panel notes that none of these studies 
tested the sustainability of an effect of beta-glucans on appetite ratings and subsequent energy intake 
(i.e. effects were tested on a single occasion and no information has been provided on the repeated 
consumption of the food constituent). The Panel considers that no conclusions can be drawn from 
these studies for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of beta-glucans from oats and barley and a sustained increase in satiety leading to a 
reduction in energy intake. 
3.2. Reduction of post-prandial glycaemic responses (ID 821, 824) 
The references provided for the scientific substantiation of the claim included publications on the 
health effects of dietary fibre in general, on the health effects of low glycaemic foods and/or diets, and 
on the effects of barley and/or oat products and/or beta-glucans on health outcomes unrelated to the 
claimed effect (e.g. blood lipids). The references also included human intervention studies which 
reported on measures of blood glucose in which the amount of beta-glucans consumed was not 
specified (Granfeldt et al., 1994; Liljeberg et al., 1992), or in which the study population was 
insulin-dependent or non-insulin dependent diabetic subjects on either insulin or oral hypoglycaemic 
medications (Braaten et al., 1994; Jenkins et al., 2002; Pick et al., 1996; Pick et al., 1998; Tappy et al., 
1996). The evidence provided does not establish that results obtained in patient populations treated 
with anti-diabetic medications can be generalised to the target population with respect to post-prandial 
glycaemic responses. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
Three human intervention studies investigated the effects of barley and/or oat beta-glucans on post-
prandial glycaemic and insulinaemic responses in healthy subjects using a standardised meal protocol 
in which whole-meal bread products (from oats, barley, and rye) were compared to white wheat bread 
(Juntunen et al., 2002; Liljeberg et al., 1996; Östman et al., 2006). All of these studies had a 
randomised cross-over design with washout periods longer than three days, and sample sizes between 
9 and 20 subjects (men and women). Two out of the three studies (Liljeberg et al., 1996; Östman et 
al., 2006) observed a statistically significant reduction in post-prandial glycaemic and insulinaemic 
responses following consumption of the test meals which included beta-glucan-containing products 
(from oats or barley), compared to the test meals not containing beta-glucans, at doses between 
4.6-14 g beta-glucans per 30 g of available carbohydrates. The study by Juntunen et al. (2002) did not 
show a significant effect on post-prandial glycaemic responses of rye bread containing 5.4 g 
beta-glucans in 50 g of available carbohydrate compared to white wheat bread, whereas post-prandial 
insulinaemic responses were significantly reduced. 
Two human intervention studies investigated the effects of incorporating oat (Holm et al., 1992) or 
barley (Yokoyama et al., 1997) beta-glucans into pasta products (control pasta made with plain durum 
wheat flour) in 10 and 5 healthy subjects, respectively. These studies had a randomised cross-over 
design with washout periods longer than three days. Consumption of pasta with 12 g of beta-glucans 
in a 100 g available carbohydrate portion (about 3.6 g/30 g available carbohydrates) resulted in 
significantly lower and delayed peak glucose responses, and in lower peak insulin responses 
Beta-glucans from oats and barley related health claims 
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(Yokoyama et al., 1997), whereas enrichment with oat bran (28 %) giving 6 % beta-glucans in the 
final product only slightly decreased post-prandial insulinaemic responses, while post-prandial 
glycaemic responses were unchanged compared to the control pasta (Holm et al., 1992). 
Another test meal study, which investigated the effects on post-prandial blood glucose and insulin 
responses of oat and barley beta-glucan products in healthy subjects, used a standardised protocol in 
which sucrose was used as a control (Behall et al., 2005). Ten overweight women (mean age 50.1±7.7 
years; BMI 30.3±2.2 kg/m
2
) consumed glucose (1 g/kg body weight) and four test meals consisting of 
0.33 g/kg body weight of carbohydrate from pudding (predominantly sucrose) plus 0.67 g/kg body 
weight of carbohydrates from oat flour, oatmeal, barley flour, or barley flakes to constitute a total of 
1 g carbohydrates/kg body weight at breakfast after a 10 h fast. The content of beta-glucans in the test 
food grains was 4 and 15 g/100 g dry matter in the oat and barley test foods, respectively (about 
1.8 and 6.5 g/30 g available carbohydrates, respectively). Blood samples were collected at fasting and 
every 30 min up to 180 min after the acute loads. Peak glucose and insulin concentrations after the 
barley test foods were significantly lower than those after the glucose or oat test foods. Post-prandial 
glucose responses (area under the curve) were significantly reduced after the consumption of oat and 
barley test foods when compared to sucrose. Post-prandial glucose responses after barley (flour and 
flakes) were significantly lower than the post-prandial glucose responses after oat (flour and oatmeal). 
Post-prandial insulinaemic responses were significantly reduced by barley test foods only (44-56 %, 
p<0.005). The content of beta-glucans in the barley test foods was almost four times higher than in the 
oat test foods, which could have explained the differential effects of the barley and oat test foods on 
post-prandial glucose and insulin responses.  
The Panel notes that the studies above consistently show an effect of oat and barley beta-glucans in 
decreasing post-prandial glycaemic responses, without disproportionally increasing post-prandial 
insulinaemic responses, at doses of at least 4 g per 30 g of available carbohydrates. 
The mechanism by which beta-glucans from oats or barley could exert the claimed effect is well 
established, and relates to the increased viscosity of the meal bolus when beta-glucans are added. 
When the meal bolus reaches the small intestine, a high viscosity delays the rate of absorption of 
nutrients, including glucose (Battilana et al., 2001; Wood et al., 2000; Wursch and Pi-Sunyer, 1997). 
In weighing the evidence, the Panel took into account that intervention studies in healthy subjects 
consistently show an effect of oat and barley beta-glucans in decreasing post-prandial glycaemic 
responses, without disproportionally increasing post-prandial insulinaemic responses, at doses of 
about 4 g per 30 g of available carbohydrates in bread and pasta products when consumed alone or in 
the context of a meal, and that the mechanism by which beta-glucans could exert the claimed effect is 
well established. 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of beta-glucans from oats and barley and a reduction of post-prandial glycaemic 
responses. 
4. Panel’s comments on the proposed wording 
4.1. Reduction of post-prandial glycaemic responses (ID 821, 824) 
The Panel considers that the following wording reflects the scientific evidence: “Consumption of 
beta-glucans from oats or barley contributes to the reduction of the glucose rise after a meal”. 
Beta-glucans from oats and barley related health claims 
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5. Conditions and possible restrictions of use 
5.1. Reduction of post-prandial glycaemic responses (ID 821, 824) 
In order to obtain the claimed effect, 4 g of beta-glucans from oats or barley for each 30 g of available 
carbohydrates should be consumed per meal. The target population is individuals who wish to reduce 
their post-prandial glycaemic responses. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, beta-glucans from oats and barley, which is the subject of the health 
claims, is sufficiently characterised. 
Maintenance of normal blood LDL-cholesterol concentrations (ID 1236, 1299) 
 The claimed effects are “fibres solubles (beta-glucane) et cholestérol sanguin” and “blood 
cholesterol level”. The target population is assumed to be the general population. In the 
context of the proposed wordings, it is assumed that the claimed effects refer to the 
maintenance of normal blood LDL-cholesterol concentrations. 
 A claim on beta-glucans and maintenance of normal blood cholesterol concentrations has 
already been assessed with a favourable outcome. 
Increase in satiety leading to a reduction in energy intake (ID 851, 852) 
 The claimed effect is “increases satiety, prolongs satiety”. The target population is assumed to 
be the general population. An increase in satiety leading to a reduction in energy intake, if 
sustained, might be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of beta-
glucans from oats and barley and a sustained increase in satiety leading to a reduction in 
energy intake. 
Reduction of post-prandial glycaemic responses (ID 821, 824) 
 The claimed effect is “carbohydrate metabolism and insulin sensitivity”. The target 
population is assumed to be individuals who wish to reduce their post-prandial glycaemic 
responses. In the context of the proposed wordings, it is assumed that the claimed effect refers 
to the reduction of post-prandial glycaemic responses. Reduction of post-prandial glycaemic 
responses (as long as post-prandial insulinaemic responses are not disproportionally 
increased) may be a beneficial physiological effect. 
 A cause and effect relationship has been established between the consumption of beta-glucans 
from oats and barley and a reduction of post-prandial glycaemic responses. 
 The following wording reflects the scientific evidence: “Consumption of beta-glucans from 
oats or barley contributes to the reduction of the glucose rise after a meal”. 
 In order to obtain the claimed effect, 4 g of beta-glucans from oats or barley for each 30 g of 
available carbohydrates should be consumed per meal. The target population is individuals 
who wish to reduce their post-prandial glycaemic responses. 
“Digestive function” (ID 850) 
 The claimed effect is “beta-glucan improves digestive function”. The target population is 
assumed to be the general population. “Improving digestive function” without an indication of 
the nutrients which are the target of the claim, is not sufficiently defined. 
Beta-glucans from oats and barley related health claims 
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 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1608, 
EFSA-Q-2008-1611, EFSA-Q-2008-1637, EFSA-Q-2008-1638, EFSA-Q-2008-1639, EFSA-Q-2008-
1974, EFSA-Q-2008-2037). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to beta-glucans from oats and barley, including conditions 
of use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
821 Barley grain fibre Carbohydrate 
metabolism and insulin 
sensitivity 
Clarification provided 
Helps to balance blood 
glucose/insulin.  
Helps to maintain 
normal blood 
glucose/insulin levels. 
Stabilises sugar metabolism. 
Conditions of use 
- Bakery products which contain beta-glucan of barley grain fibre ≥3g/daily serving. Amount: 
6g/100g of oat grain fibre. Processing of the product may weaken the utilisation of beta-
glucan in the body and its health impacts. Content, viscosity, solubility and molecular 
weight of beta-glucan in the products should be specified to be able to refer to the utilisation 
of the beta-glucan present in the product. 
- Crushed and whole barley grits with 12g/100g of fibre, 6g/serving and low glycemic index 
< 55. Coarse particles slow down absorption. 
Comments from Member States 
Health relationship defined 
ID Food or Food constituent Health Relationship Proposed wording 
824 Oat grain fibre Carbohydrate 
metabolism and insulin 
sensitivity. 
Clarification provided 
Helps to balance blood 
glucose/insulin.  
Helps to maintain 
normal blood 
glucose/insulin levels. 
Stabilises sugar metabolism. 
Conditions of use 
- Bakery products with ≥3g/100g of beta-glucan of oat grain fibre. Amount: 6g/100g of oat 
grain fibre. Processing of the product may weaken the utilisation of beta-glucan in the body 
and its health impacts. Content, viscosity, solubility and molecular weight of beta-glucan in 
the products should be specified to be able to refer to the utilisation of the beta-glucan 
present in the product. 
- Dark, fibre-rich pasta with 6-11g/100g of oat, rye and wheat fibre, 4-7g/serving and 
glycemic index <55. Preparation process of pasta changes starch into more slowly absorbing 
form and the compact structure slows down absorption. Other substances consumed at the 
same meal influence the glycemic index. 
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 Comments from Member States 
Health relationship defined 
ID Food or Food constituent Health Relationship Proposed wording 
850 Oats beta-glucan Beta-glucan improves 
digestive function. 
Kaera kiudaine beeta-glükaani 
tarbimine soodustab seedimist. Kaera 
kiudaine beeta-glükaani tarbimine 
aitab soodustada seedimist. 
Clarification provided 
Consuming beta-glucan promotes 
digestion, improves digestive 
function. 
Conditions of use 
- Tootja poolt esitatud andmete põhjal on beeta-glükaani päevane soovitatav kogus 3 g, 
märgistuselt peaks ilmnema, kui suure koguse sellest toode annab.  
Comments from Member States 
Consuming beta-glucan promotes digestion, improves digestive function. 
ID Food or Food constituent Health Relationship Proposed wording 
851 Oats beta-glucan 
 
Beta-glucan increases 
satiety, prolongs satiety. 
Kaera kiudaine beeta-glükaani 
tarbimine suurendab küllastustunnet 
ehk täiskõhutunnet.Kaera kiudaine 
beeta-glükaani tarbimine pikendab 
küllastustunde ehk täiskõhutunde 
säilimist. 
Clarification provided 
Consuming oats beta-glucan 
increases satiety. Consuming oats 
beta-glucan prolongs the feeling of 
satiety. 
Conditions of use 
- Tootja poolt esitatud andmete põhjal on beeta-glükaani päevane soovitatav kogus 3 g, 
märgistuselt peaks ilmnema, kui suure koguse sellest toode annab. 
Comments from Member States 
Consuming oats beta-glucan increases satiety. Consuming oats beta-glucan prolongs the feeling 
of satiety. 
ID Food or Food constituent Health Relationship Proposed wording 
852 Barley beta-glucan Beta-glucan increases 
satiety, prolongs satiety. 
Odra kiudaine beeta-glükaani 
tarbimine suurendab küllastustunnet 
ehk täiskõhutunnet. Odra kiudaine 
beeta-glükaani tarbimine pikendab 
küllastustunde ehk täiskõhutunde 
säilimist. 
Clarification provided 
Consuming barley beta-glucan 
increases satiety. Consuming oats 
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beta-glucan prolongs the feeling of 
satiety. 
Conditions of use 
- Tootja poolt esitatud andmete põhjal on beeta-glükaani päevane soovitatav kogus 3 g, 
märgistuselt peaks ilmnema, kui suure koguse sellest toode annab. 
 Comments from Member States 
Consuming barley beta-glucan increases satiety. Consuming oats beta-glucan prolongs the 
feeling of satiety. 
ID Food or Food constituent Health Relationship Proposed wording 
1236 Barre céréalière diététique 
contenant de l'avoine 
Fibres solubles (Beta-
glucane) et cholestérol 
sanguin. 
 
Conditions of use 
- 750 mg de beta-glucane par portion soit au moins 1 portion par jour. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1299 Oatbran and oatbran 
products 
 
Blood cholesterol level. 
 
 
Oat bran or oat products containing 
bran may help to maintain normal 
blood cholesterol level. 
 
Conditions of use 
- Minimum 100 g/day. 
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GLOSSARY AND ABBREVIATIONS 
BMI  Body mass index 
 
